Skip to content
Markets
This is research, not advice. We’re not SEBI-registered.
Industry · 28 scored · 51 listed

Drug Manufacturers - Specialty & Generic Stocks in the US

The 28 Drug Manufacturers - Specialty & Generic companies we score in the US are Teva Pharmaceutical Industries Limited ($48.7B, the largest), Haleon plc, Zoetis Inc. and 25 more. 15 of the 28 companies we score beat S&P 500 on share price over recent months. Prices are as of 4 Nov 2026.

Drug Manufacturers - Specialty & Generic: Teva Pharmaceutical Industries Limited owns the largest revenue base; Liquidia Corporation has the fastest current growth.

28Companies scored on this page, of 51 listed
$280.2BCombined market value all of them together
20/24Revenue growing revenue over the last 12 months up on a year earlier
15/28Beating S&P 500 share price doing better than the index (relative strength)
15 of 28 beat the S&P 500 on share price over recent months

The main question: the biggest companies are not always the ones changing the most.

Start with size. Then the direction of earnings. Then the quality of the business. A share price that leads means more once those three agree.

By Sector AlphaUpdated November 2026Prices as of 4 November 2026How the numbers are worked out

Which are the biggest Drug Manufacturers - Specialty & Generic stocks in the US?

The largest Drug Manufacturers - Specialty & Generic stocks in the US by market value are Teva Pharmaceutical Industries ($48.7B), Haleon plc ($41.9B) and Zoetis Inc. ($36.8B), at prices of 4 Nov 2026.

The other 18 Drug Manufacturers - Specialty & Generic companies are in the full list below.

Share price | market value | P/E, biggest first. Prices and market values as of 4 Nov 2026; ratios as in the score list below.

Which are the Drug Manufacturers - Specialty & Generic stocks, ranked?

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 4 Nov 2026.

  1. 1Neurocrine Biosciences, Inc.NBIX · $16.8B66.3of 100favourable · strongest on PEG and ROCE
  2. 2Indivior Pharmaceuticals, Inc.INDV · $3.3B63.2of 100mixed, leaning good · strongest on ROCE and ROCE improvement
  3. 3Kiniksa Pharmaceuticals International, plcKNSA · $7.6B62.1of 100mixed, leaning good · strongest on relative strength versus sector and profit growth
  4. 4Bausch Health Companies Inc.BHC · $3.1B60.1of 100mixed, leaning good · strongest on relative strength versus sector and ROCE improvement
  5. 5Xeris Biopharma Holdings, Inc.XERS · $1.9B60.0of 100mixed, leaning good · strongest on relative strength versus sector and ROCE improvement
  6. 6Phibro Animal Health CorporationPAHC · $1.6B58.6of 100mixed, leaning good · strongest on profit growth and ROCE improvement
  7. 7Amneal Pharmaceuticals, Inc.AMRX · $6.9B58.6of 100mixed, leaning good · strongest on profit growth and relative strength versus sector
  8. 8BioCryst Pharmaceuticals, Inc.BCRX · $2.1B58.3of 100mixed, leaning good · strongest on ROCE and ROCE improvement
  9. 9Liquidia CorporationLQDA · $4.2B55.8of 100mixed, leaning good · strongest on ROCE and ROCE improvement
  10. 10United Therapeutics CorporationUTHR · $26.1B55.4of 100mixed, leaning good · strongest on ROCE and profitable quarters

Which Drug Manufacturers - Specialty & Generic companies are listed in the US?

The largest 15 of 28 listed US Drug Manufacturers - Specialty & Generic companies are named here; all 28 are ranked in the scorecard. Every figure is equal-weighted across those companies and carries its own as-of date. One large company cannot set the reading.

  1. Teva Pharmaceutical Industries Limited$48.7B
  2. Haleon plc$41.9B
  3. Zoetis Inc.$36.8B
  4. United Therapeutics Corporation$26.1B
  5. Viatris Inc.$22.1B
  6. Neurocrine Biosciences, Inc.$16.8B
  7. Elanco Animal Health Incorporated$12.6B
  8. Alkermes plc$7.7B
  9. Kiniksa Pharmaceuticals International, plc$7.6B
  10. Amneal Pharmaceuticals, Inc.$6.9B
  11. Lantheus Holdings, Inc.$6.6B
  12. Hims & Hers Health, Inc.$6.2B
  13. Liquidia Corporation$4.2B
  14. Amylyx Pharmaceuticals, Inc.$3.7B
  15. Indivior Pharmaceuticals, Inc.$3.3B

The remaining 13 Drug Manufacturers - Specialty & Generic companies are named and ranked in the scorecard.

How many Drug Manufacturers - Specialty & Generic companies are listed in the US?

51 Drug Manufacturers - Specialty & Generic companies in the Drug Manufacturers - Specialty & Generic industry group (every listed company) have a page on Sector Alpha, by market value as of 4 November 2026, and all 51 are listed below, largest first. The largest is Takeda Pharmaceutical Company ($66.4 billion) and the smallest with a market value is Journey Medical Corporation.

Every Drug Manufacturers - Specialty & Generic company with a page, largest first
CompanyMarket value
1. Takeda Pharmaceutical Company Limited TAK$66.4 billion
2. Teva Pharmaceutical Industries Limited TEVA$48.7 billion
3. Haleon plc HLN$41.9 billion
4. Zoetis Inc. ZTS$36.8 billion
5. United Therapeutics Corporation UTHR$26.1 billion
6. Viatris Inc. VTRS$22.1 billion
7. Neurocrine Biosciences, Inc. NBIX$16.8 billion
8. Elanco Animal Health Incorporated ELAN$12.6 billion
9. Dr. Reddy's Laboratories Limited RDY$12.1 billion
10. Alkermes plc ALKS$7.7 billion
11. Kiniksa Pharmaceuticals International, plc KNSA$7.6 billion
12. Amneal Pharmaceuticals, Inc. AMRX$6.9 billion
13. Lantheus Holdings, Inc. LNTH$6.6 billion
14. Hims & Hers Health, Inc. HIMS$6.2 billion
15. Liquidia Corporation LQDA$4.2 billion
16. Amylyx Pharmaceuticals, Inc. AMLX$3.7 billion
17. Indivior Pharmaceuticals, Inc. INDV$3.3 billion
18. Supernus Pharmaceuticals, Inc. SUPN$3.3 billion
19. Bausch Health Companies Inc. BHC$3.1 billion
20. Prestige Consumer Healthcare Inc. PBH$2.5 billion
21. HUTCHMED (China) Limited HCM$2.4 billion
22. Trulieve Cannabis Corp. TRLV$2.2 billion
23. Perrigo Company plc PRGO$2.2 billion
24. BioCryst Pharmaceuticals, Inc. BCRX$2.1 billion
25. Xeris Biopharma Holdings, Inc. XERS$1.9 billion
26. Alvotech ALVO$1.7 billion
27. Phibro Animal Health Corporation PAHC$1.6 billion
28. ANI Pharmaceuticals, Inc. ANIP$1.5 billion
29. Pacira BioSciences, Inc. PCRX$1.5 billion
30. Eton Pharmaceuticals, Inc. ETON$1.4 billion
31. Cronos Group Inc. CRON$1.3 billion
32. Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion
33. Harrow, Inc. HROW$1.1 billion
34. Esperion Therapeutics, Inc. ESPR$819 million
35. Collegium Pharmaceutical, Inc. COLL$771 million
36. Ironwood Pharmaceuticals, Inc. IRWD$623 million
37. Evotec SE EVO$576 million
38. Evolus, Inc. EOLS$493 million
39. Aquestive Therapeutics, Inc. AQST$478 million
40. Alpha Teknova, Inc. TKNO$455 million
41. Tilray Brands, Inc. TLRY$434 million
42. Kamada Ltd. KMDA$408 million
43. Aurora Cannabis Inc. ACB$344 million
44. Canopy Growth Corporation CGC$318 million
45. Emergent BioSolutions Inc. EBS$303 million
46. Anika Therapeutics, Inc. ANIK$273 million
47. Lifecore Biomedical, Inc. LFCR$244 million
48. SIGA Technologies, Inc. SIGA$226 million
49. ADC Therapeutics SA ADCT$220 million
50. Akebia Therapeutics, Inc. AKBA$193 million
51. Journey Medical Corporation DERM$134 million

Download all 51 Drug Manufacturers - Specialty & Generic companies (CSV)

How has Drug Manufacturers - Specialty & Generic moved against S&P 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this industry is 44% ahead of S&P 500. Earnings across its companies fell 17% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 5 weeks running.

Breaking out · ahead 5w ~

Price up, without the fundamentals confirming. 25 of 51 companies ahead of S&P 500 by 5% or more over three months. 1 is 20% or more behind over a year while earnings grew 20% or more.

Ahead of S&P 500 on the three-month view for 5 weeks running; 30 of the 51 companies in the industry index above their 200-day average (1 more than four weeks earlier); 25 of those 51 ahead of S&P 500 by 5% or more over three months (no change from four weeks earlier); earnings rising at 29 of the 50 that report earnings.

Ahead of S&P 500 for 5 weeks running, participation steady at 25 → 25 of 51. Earnings mixed, 29 of 50 members have higher trailing twelve-month earnings than a year ago.

1Y

Drug Manufacturers - Specialty & Generic against S&P 500

Both lines start at 200 in the first week shown

  • Drug Manufacturers - Specialty & Generic 249
  • S&P 500 228
Drug Manufacturers - Specialty & Generic against S&P 500
Week endingDrug Manufacturers - Specialty & GenericS&P 500
14 Nov 2025200200
21 Nov 2025198196
28 Nov 2025207203
5 Dec 2025210204
12 Dec 2025221203
19 Dec 2025220203
26 Dec 2025220205
2 Jan 2026218203
9 Jan 2026224207
16 Jan 2026220206
23 Jan 2026222205
30 Jan 2026217206
6 Feb 2026222206
13 Feb 2026219203
20 Feb 2026221205
27 Feb 2026219204
6 Mar 2026209200
13 Mar 2026206197
20 Mar 2026204193
27 Mar 2026201189
3 Apr 2026211195
10 Apr 2026213202
17 Apr 2026226211
24 Apr 2026220213
1 May 2026228215
8 May 2026227220
15 May 2026217220
22 May 2026221222
29 May 2026225225
5 Jun 2026221220
12 Jun 2026226221
19 Jun 2026226222
26 Jun 2026234217
3 Jul 2026238222
10 Jul 2026232225
17 Jul 2026230221
24 Jul 2026224220
31 Jul 2026231222
7 Aug 2026236230
14 Aug 2026238231
21 Aug 2026247228
28 Aug 2026246229
4 Sep 2026250229
11 Sep 2026237227
18 Sep 2026241227
25 Sep 2026244230
2 Oct 2026238229
9 Oct 2026245232
16 Oct 2026238227
23 Oct 2026239226
30 Oct 2026246225
6 Nov 2026249228

3Y

Drug Manufacturers - Specialty & Generic against S&P 500

Both lines start at 200 in the first week shown, every 2nd week shown

  • Drug Manufacturers - Specialty & Generic 488
  • S&P 500 340
Drug Manufacturers - Specialty & Generic against S&P 500
Week endingDrug Manufacturers - Specialty & GenericS&P 500
17 Nov 2023200200
24 Nov 2023204202
8 Dec 2023209204
22 Dec 2023220210
5 Jan 2024229208
19 Jan 2024223214
2 Feb 2024230219
16 Feb 2024240222
1 Mar 2024248228
15 Mar 2024237226
29 Mar 2024239232
12 Apr 2024220227
26 Apr 2024222226
10 May 2024230231
24 May 2024228235
7 Jun 2024231237
21 Jun 2024230242
5 Jul 2024228246
19 Jul 2024238244
2 Aug 2024244236
16 Aug 2024253246
30 Aug 2024259250
13 Sep 2024255249
27 Sep 2024261254
11 Oct 2024267257
25 Oct 2024271257
8 Nov 2024283265
22 Nov 2024273264
6 Dec 2024278270
20 Dec 2024268262
3 Jan 2025273263
17 Jan 2025270265
31 Jan 2025270267
14 Feb 2025267271
28 Feb 2025264264
14 Mar 2025268250
28 Mar 2025267247
11 Apr 2025244237
25 Apr 2025266244
9 May 2025297250
23 May 2025304257
6 Jun 2025324266
20 Jun 2025325264
4 Jul 2025329277
18 Jul 2025325278
1 Aug 2025321276
15 Aug 2025368285
29 Aug 2025383286
12 Sep 2025387292
26 Sep 2025391294
10 Oct 2025392290
24 Oct 2025407300
7 Nov 2025387298
21 Nov 2025387292
5 Dec 2025411304
19 Dec 2025430302
2 Jan 2026426303
16 Jan 2026429307
30 Jan 2026425307
13 Feb 2026427302
27 Feb 2026428304
13 Mar 2026404294
27 Mar 2026392281
10 Apr 2026417301
24 Apr 2026430317
8 May 2026445327
22 May 2026432331
5 Jun 2026432327
19 Jun 2026442331
3 Jul 2026466330
17 Jul 2026450330
31 Jul 2026453331
14 Aug 2026466344
28 Aug 2026482341
11 Sep 2026463339
25 Sep 2026477342
9 Oct 2026480345
23 Oct 2026467337
6 Nov 2026488340

5Y

Drug Manufacturers - Specialty & Generic against S&P 500

Both lines start at 200 in the first week shown, every 4th week shown

  • Drug Manufacturers - Specialty & Generic 537
  • S&P 500 327
Drug Manufacturers - Specialty & Generic against S&P 500
Week endingDrug Manufacturers - Specialty & GenericS&P 500
19 Nov 2021200200
10 Dec 2021191201
7 Jan 2022201199
4 Feb 2022197191
4 Mar 2022201184
1 Apr 2022206193
29 Apr 2022185176
27 May 2022182177
24 Jun 2022188166
22 Jul 2022195169
19 Aug 2022202180
16 Sep 2022193164
14 Oct 2022184153
11 Nov 2022205170
9 Dec 2022213168
6 Jan 2023220166
3 Feb 2023228176
3 Mar 2023223172
31 Mar 2023209175
28 Apr 2023214177
26 May 2023213179
23 Jun 2023222185
21 Jul 2023230193
18 Aug 2023224186
15 Sep 2023230189
13 Oct 2023218184
10 Nov 2023215188
8 Dec 2023230196
5 Jan 2024252200
2 Feb 2024253211
1 Mar 2024274219
29 Mar 2024263223
26 Apr 2024244217
24 May 2024252226
21 Jun 2024253232
19 Jul 2024262234
16 Aug 2024279236
13 Sep 2024281240
11 Oct 2024294247
8 Nov 2024312255
6 Dec 2024306259
3 Jan 2025301252
31 Jan 2025297257
28 Feb 2025291253
28 Mar 2025295237
25 Apr 2025293235
23 May 2025334247
20 Jun 2025359253
18 Jul 2025358268
15 Aug 2025405274
12 Sep 2025427280
10 Oct 2025432279
7 Nov 2025426286
5 Dec 2025453292
2 Jan 2026469291
30 Jan 2026468295
27 Feb 2026471293
27 Mar 2026432270
24 Apr 2026474305
22 May 2026476318
19 Jun 2026487319
17 Jul 2026496317
14 Aug 2026513331
11 Sep 2026510326
9 Oct 2026528332
6 Nov 2026537327

Earnings, each company rebased to 100, the sector takes the median

Latest quarter April to June 2026: 88.5, from 17 companies

Earnings, each company rebased to 100, the sector takes the median
QuarterMedian earnings index
Jan 2022100.0 (17 companies)
Apr 202280.7 (18 companies)
Jul 202279.0 (17 companies)
Oct 202255.6 (18 companies)
Jan 202348.5 (17 companies)
Apr 202321.0 (18 companies)
Jul 202316.0 (17 companies)
Oct 202362.7 (18 companies)
Jan 2024103.2 (17 companies)
Apr 202496.9 (18 companies)
Jul 2024101.7 (17 companies)
Oct 202495.1 (18 companies)
Jan 202572.3 (17 companies)
Apr 202586.3 (18 companies)
Jul 2025100.0 (17 companies)
Oct 202564.7 (18 companies)
Jan 202684.7 (16 companies)
Apr 202688.5 (17 companies)

Both lines start at 200 in the same week, so the gap between them tells the story: the industry line is an equal-weighted index of its 51 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the industry taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Is Drug Manufacturers - Specialty & Generic outperforming S&P 500?

Drug Manufacturers - Specialty & Generic has done better than the S&P 500 by 22.3% over the last 52 weeks. Over 13 weeks the gap is a lead of 11.9%. Kiniksa Pharmaceuticals International, plc is the strongest against the sector itself at +43.2%.

+11.9%Sector vs S&P 500 · 13 weeks
+22.3%Sector vs S&P 500 · 52 weeks
15 of 28Stocks leading S&P 500
11 of 28Stocks leading the sector

What is the bottom line on Drug Manufacturers - Specialty & Generic?

Drug Manufacturers - Specialty & Generic has done better than the S&P 500 by 22.3% over 52 weeks and by 11.9% over 13 weeks. 15 of 28 companies we track are beating the S&P 500 on relative strength (how a share price has done against the index over recent months), and 11 of 28 are ahead of the industry itself.

How does each Drug Manufacturers - Specialty & Generic stock score?

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Growth & earnings · 35% Capital efficiency · 25% Valuation · 20% Relative strength · 20%

Neurocrine Biosciences, Inc. has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 81.1% evidence confidence.

Alkermes plc scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

  1. 1Neurocrine Biosciences, Inc.NBIX · turning · favourable · 81% evidence66.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.1/35 · Revenue 34.4% · PAT 100% · OPM change 1 pp · 83% evidenceCapital efficiency 18.2/25 · ROCE 19.3% · OPM 22.2% · 76% evidenceValuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidenceRelative strength 8.2/20 · RS sector −5.3% · RS bench 6.1% · 1Y 9% · 100% evidence · 0 of 12 weeks aheadExact sum: 26.1 + 18.2 + 13.8 + 8.2 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Indivior Pharmaceuticals, Inc.INDV · quiet · mixed, leaning good · 71% evidence63.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 27.8/35 · Revenue 13.5% · PAT 100% · OPM change 23.4 pp · 83% evidenceCapital efficiency 20.8/25 · ROCE 152.3% · OPM 46.9% · 76% evidenceValuation 10.3/20 · P/E 14.1× · PEG — · 15% evidenceRelative strength 4.3/20 · RS sector −13.9% · RS bench −3.7% · 1Y 15.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 27.8 + 20.8 + 10.3 + 4.3 = 63.2 · What this means: Earnings are strong; relative strength in its sector is −13.9% and the one-year return is 15.8%.
  3. 3Kiniksa Pharmaceuticals International, plcKNSA · leader · mixed, leaning good · 71% evidence62.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.1/35 · Revenue 58.7% · PAT 100% · OPM change −1.7 pp · 83% evidenceCapital efficiency 12.2/25 · ROCE 13.8% · OPM 11.2% · 76% evidenceValuation 9.0/20 · P/E 61× · PEG — · 15% evidenceRelative strength 16.8/20 · RS sector 43.2% · RS bench 59% · 1Y 150.5% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.1 + 12.2 + 9 + 16.8 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  4. 4Bausch Health Companies Inc.BHC · leader · mixed, leaning good · 71% evidence60.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.9/35 · Revenue 10.1% · PAT −1220.4% · OPM change 9.1 pp · 83% evidenceCapital efficiency 12.8/25 · ROCE 13.5% · OPM 27.2% · 76% evidenceValuation 10.9/20 · P/E −1.7× · PEG — · 15% evidenceRelative strength 18.5/20 · RS sector 17.1% · RS bench 30.9% · 1Y 25.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 17.9 + 12.8 + 10.9 + 18.5 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  5. 5Xeris Biopharma Holdings, Inc.XERS · leader · mixed, leaning good · 64% evidence60.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.1/35 · Revenue 36.2% · PAT — · OPM change −0.7 pp · 62% evidenceCapital efficiency 11.8/25 · ROCE 16.5% · OPM 5.6% · 76% evidenceValuation 8.7/20 · P/E 83.3× · PEG — · 15% evidenceRelative strength 18.4/20 · RS sector 18.3% · RS bench 31.8% · 1Y 40.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 21.1 + 11.8 + 8.7 + 18.4 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Phibro Animal Health CorporationPAHC · breaking out · mixed, leaning good · 81% evidence58.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.4/35 · Revenue 17.2% · PAT 100% · OPM change 0.3 pp · 83% evidenceCapital efficiency 15.3/25 · ROCE 16.4% · OPM 10.6% · 76% evidenceValuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidenceRelative strength 7.1/20 · RS sector −19.8% · RS bench −10.4% · 1Y −9.9% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.4 + 15.3 + 11.8 + 7.1 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  7. 7Amneal Pharmaceuticals, Inc.AMRX · leader · mixed, leaning good · 71% evidence58.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.4/35 · Revenue 9.3% · PAT 100% · OPM change 2.8 pp · 83% evidenceCapital efficiency 15.1/25 · ROCE 17.1% · OPM 18.3% · 76% evidenceValuation 9.3/20 · P/E 35.1× · PEG — · 15% evidenceRelative strength 12.8/20 · RS sector 11.3% · RS bench 23.9% · 1Y 75.5% · 100% evidence · 10 of 12 weeks aheadExact sum: 21.4 + 15.1 + 9.3 + 12.8 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8BioCryst Pharmaceuticals, Inc.BCRX · quiet · mixed, leaning good · 64% evidence58.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.6/35 · Revenue 68.5% · PAT — · OPM change 26.9 pp · 62% evidenceCapital efficiency 18.1/25 · ROCE 112% · OPM 45.1% · 76% evidenceValuation 11.0/20 · P/E −6.6× · PEG — · 15% evidenceRelative strength 3.6/20 · RS sector −18% · RS bench −8.4% · 1Y 16.2% · 100% evidence · 3 of 12 weeks aheadExact sum: 25.6 + 18.1 + 11 + 3.6 = 58.3 · What this means: Earnings are strong; relative strength in its sector is −18% and the one-year return is 16.2%.
  9. 9Liquidia CorporationLQDA · quiet · mixed, leaning good · 64% evidence55.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.0/35 · Revenue 100% · PAT — · OPM change 474.2 pp · 62% evidenceCapital efficiency 17.9/25 · ROCE 50.7% · OPM 49.8% · 76% evidenceValuation 9.2/20 · P/E 51.2× · PEG — · 15% evidenceRelative strength 2.7/20 · RS sector −19.6% · RS bench −10.2% · 1Y 81.6% · 100% evidence · 3 of 12 weeks aheadExact sum: 26 + 17.9 + 9.2 + 2.7 = 55.8 · What this means: Earnings are strong; relative strength in its sector is −19.6% and the one-year return is 81.6%.
  10. 10United Therapeutics CorporationUTHR · turning · mixed, leaning good · 81% evidence55.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 14.5/35 · Revenue 2.5% · PAT 5.6% · OPM change −6.2 pp · 83% evidenceCapital efficiency 20.3/25 · ROCE 21.2% · OPM 42.2% · 76% evidenceValuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidenceRelative strength 11.4/20 · RS sector −2.5% · RS bench 8.9% · 1Y 35.5% · 100% evidence · 3 of 12 weeks aheadExact sum: 14.5 + 20.3 + 9.2 + 11.4 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Viatris Inc.VTRS · breaking out · mixed, leaning good · 64% evidence52.4out of 100GrowthCapitalValuationRelative
  12. 12Trulieve Cannabis Corp.TRLV · breaking out · mixed, leaning good · 64% evidence50.8out of 100GrowthCapitalValuationRelative
  13. 13Pacira BioSciences, Inc.PCRX · breaking out · mixed, leaning good · 64% evidence50.3out of 100GrowthCapitalValuationRelative
  14. 14ANI Pharmaceuticals, Inc.ANIP · basing · mixed, leaning weak · 64% evidence48.3out of 100GrowthCapitalValuationRelative
  15. 15Zoetis Inc.ZTS · turning · mixed, leaning weak · 81% evidence47.1out of 100GrowthCapitalValuationRelative
  16. 16Teva Pharmaceutical Industries LimitedTEVA · leader · mixed, leaning weak · 64% evidence46.9out of 100GrowthCapitalValuationRelative
  17. 17Haleon plcHLN · basing · provisional · 56% evidence46.2out of 100GrowthCapitalValuationRelative
  18. 18Perrigo Company plcPRGO · breaking out · mixed, leaning weak · 64% evidence45.1out of 100GrowthCapitalValuationRelative
  19. 19Elanco Animal Health IncorporatedELAN · turning · mixed, leaning weak · 71% evidence44.9out of 100GrowthCapitalValuationRelative
  20. 20Lantheus Holdings, Inc.LNTH · turning · mixed, leaning weak · 81% evidence43.8out of 100GrowthCapitalValuationRelative
  21. 21Alkermes plcALKS · quiet · mixed, leaning weak · 81% evidence43.6out of 100GrowthCapitalValuationRelative
  22. 22HUTCHMED (China) LimitedHCM · breaking out · provisional · 51% evidence40.8out of 100GrowthCapitalValuationRelative
  23. 23Prestige Consumer Healthcare Inc.PBH · basing · mixed, leaning weak · 71% evidence37.8out of 100GrowthCapitalValuationRelative
  24. 24AlvotechALVO · breaking out · weak · 71% evidence33.7out of 100GrowthCapitalValuationRelative
  25. 25Hims & Hers Health, Inc.HIMS · quiet · weak · 71% evidence27.4out of 100GrowthCapitalValuationRelative
  26. 26Supernus Pharmaceuticals, Inc.SUPN · quiet · weak · 71% evidence26.6out of 100GrowthCapitalValuationRelative

Ranked last: too little evidence (2 companies)

Under 60% of the evidence behind these scores is available, so they rank after every company above, whatever the score.

  1. 27Amylyx Pharmaceuticals, Inc.AMLX · leader · provisional · 40% evidence47.7out of 100GrowthCapitalValuationRelative
  2. 28Regencell Bioscience Holdings LimitedRGC · fading · provisional · 47% evidence30.6out of 100GrowthCapitalValuationRelative
How this score is built, and what the marks mean

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

How have Drug Manufacturers - Specialty & Generic share prices moved?

Kiniksa Pharmaceuticals International, plc has the strongest one-year price move in Drug Manufacturers - Specialty & Generic at +150.5%. It also leads on relative strength against the S&P 500, at +59.0%. 15 of 28 companies we track are ahead of the index on that measure. Every line covers 314 weekly closes through 4 November 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs S&P 500: How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Drug Manufacturers - Specialty & Generic itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

1Y

Price of the 5 strongest one-year movers, each started at 100

52 weekly closes

  • Kiniksa 238
  • Amylyx 232
  • Lantheus Holdings, Inc. 191
  • Viatris Inc. 179
  • Liquidia Corporation 169
  • S&P 500 114
Price of the 5 strongest one-year movers, each started at 100
Week endingKiniksaAmylyxLantheus Holdings, Inc.Viatris Inc.Liquidia CorporationS&P 500
14 Nov 2025100100100100100100
21 Nov 20251031161059810498
28 Nov 2025106118111100116102
5 Dec 2025103112119102123102
12 Dec 2025103103126109119102
19 Dec 202510795124111123101
26 Dec 202510497126115123103
2 Jan 202610490127116112102
9 Jan 202610696127119128103
16 Jan 202698113121120135103
23 Jan 2026105124127123145103
30 Jan 2026109113126122151103
6 Feb 2026107110122136154103
13 Feb 2026113111131147136102
20 Feb 2026119110139149120103
27 Feb 2026110120141139111102
6 Mar 2026115109137132129100
13 Mar 202611411015012613199
20 Mar 202611410914412313097
27 Mar 202611410714112212594
3 Apr 202612111814412513498
10 Apr 2026117129152126138101
17 Apr 2026111145158137141106
24 Apr 2026106134159136133106
1 May 2026137126161140136107
8 May 2026145116176160151110
15 May 2026140105177154203110
22 May 2026132107194155218111
29 May 2026120113187152221113
5 Jun 2026120105191148221110
12 Jun 2026129115197154254110
19 Jun 2026137124196143254111
26 Jun 2026147140207152279109
3 Jul 2026160144207156282111
10 Jul 2026157140199152278112
17 Jul 2026159140203161285111
24 Jul 2026156145198161308110
31 Jul 2026184160188164300111
7 Aug 2026189180190153322115
14 Aug 2026190170190151266116
21 Aug 2026196305189152245114
28 Aug 2026194274190152241115
4 Sep 2026193269191158245115
11 Sep 2026189249189154238114
18 Sep 2026192255190158239113
25 Sep 2026186232188166244115
2 Oct 2026188219189164102115
9 Oct 202619822218916598116
16 Oct 2026195208188174123114
23 Oct 2026190214188168152113
30 Oct 2026229227190178161113
6 Nov 2026238232191179169114

3Y

Price of the 5 strongest one-year movers, each started at 100

156 weekly closes, every 2nd shown

  • Kiniksa 612
  • Amylyx 244
  • Lantheus Holdings, Inc. 148
  • Viatris Inc. 203
  • Liquidia Corporation 749
  • S&P 500 170
Price of the 5 strongest one-year movers, each started at 100
Week endingKiniksaAmylyxLantheus Holdings, Inc.Viatris Inc.Liquidia CorporationS&P 500
17 Nov 2023100100100100100100
24 Nov 2023102109101100108101
8 Dec 2023110116108104114102
22 Dec 202311612087113186105
5 Jan 202411713995127200104
19 Jan 202412012478121204107
2 Feb 202411713179125215110
16 Feb 202412713284138231111
1 Mar 202413815595133229114
15 Mar 20241272785126251113
29 Mar 20241262491126233116
12 Apr 20241101789120220113
26 Apr 20241141596122198113
10 May 202412415112118191116
24 May 202412114115110196117
7 Jun 202412115117111218119
21 Jun 202411915116111193121
5 Jul 202412314116109193123
19 Jul 202413517171125175122
2 Aug 202416017143126177118
16 Aug 202416618139123223123
30 Aug 202417018156128150125
13 Sep 202416122155123155125
27 Sep 202415926157122158127
11 Oct 202416929165120175129
25 Oct 202417544162121174129
8 Nov 202414656128137174133
22 Nov 202413644133142168132
6 Dec 202413743131135174135
20 Dec 202413134131133175131
3 Jan 202512934134130194131
17 Jan 202511830134120204133
31 Jan 202512530136119225134
14 Feb 202512631117114256135
28 Feb 20251292713898245132
14 Mar 20251443014896228125
28 Mar 20251473014192238123
11 Apr 20251233015080213118
25 Apr 20251364414986223122
9 May 20251663812093241125
23 May 20251714410888243129
6 Jun 20251924412092287133
20 Jun 20251814211694208132
4 Jul 20251785211899193139
18 Jul 20251856910394230139
1 Aug 20252046410493279138
15 Aug 20252136679112410143
29 Aug 20252137881112437143
12 Sep 20252369778105411146
26 Sep 202523212074101344147
10 Oct 202524111879103366145
24 Oct 202524811782110354150
7 Nov 202524410275107412149
21 Nov 202526512282111460146
5 Dec 202526511893116544152
19 Dec 202527510097126546151
2 Jan 20262679599132496152
16 Jan 202625111994136599153
30 Jan 202628011898139670154
13 Feb 2026289117102167604151
27 Feb 2026283126110158490152
13 Mar 2026291116117143579147
27 Mar 2026291112109138553141
10 Apr 2026300136118143609151
24 Apr 2026272141124154589158
8 May 2026373122137182668164
22 May 2026339113151176963165
5 Jun 2026308110148168977164
19 Jun 20263511301521631,123166
3 Jul 20264111511611771,247165
17 Jul 20264071471581831,263165
31 Jul 20264731681461861,329166
14 Aug 20264891791481721,176172
28 Aug 20264972881481731,069171
11 Sep 20264862621471751,054170
25 Sep 20264782441461891,081171
9 Oct 2026508233147187433173
23 Oct 2026488225146191674169
6 Nov 2026612244148203749170

5Y

Price of the 5 strongest one-year movers, each started at 100

260 weekly closes, every 4th shown

  • Kiniksa 788
  • Amylyx 143
  • Lantheus Holdings, Inc. 353
  • Viatris Inc. 147
  • Liquidia Corporation 1,112
  • S&P 500 164
Price of the 5 strongest one-year movers, each started at 100
Week endingKiniksaAmylyxLantheus Holdings, Inc.Viatris Inc.Liquidia CorporationS&P 500
19 Nov 2021100–100100100100
10 Dec 2021107–9597101100
7 Jan 202290–9411314799
4 Feb 2022841099311614796
4 Mar 2022781331827815692
1 Apr 202288632038316897
29 Apr 202277442327912888
27 May 20226643245949689
24 Jun 202284912198410283
22 Jul 2022901072397312284
19 Aug 2022961212888117590
16 Sep 2022861432777114182
14 Oct 20221111682407312576
11 Nov 20221261651978811685
9 Dec 20221281731868213384
6 Jan 20231291801699313483
3 Feb 20231161782129316788
3 Mar 20231011662548517286
31 Mar 2023881422887416287
28 Apr 2023881382987115889
26 May 20231151213177019690
23 Jun 20231271123237521192
21 Jul 20231281093058019196
18 Aug 2023138982318616393
15 Sep 2023141962267515195
13 Oct 2023134842357114592
10 Nov 2023118612217014794
8 Dec 2023142682577517098
5 Jan 20241508222592297100
2 Feb 20241517718891319105
1 Mar 20241789122596341109
29 Mar 20241621421791346112
26 Apr 2024147922989294108
24 May 2024156827380292113
21 Jun 2024153927680286116
19 Jul 20241741040791260117
16 Aug 20242131033189331118
13 Sep 20242071336889230120
11 Oct 20242181739187260124
8 Nov 20241873330599259128
6 Dec 20241762531097259130
3 Jan 20251672031894289126
31 Jan 20251611832286334128
28 Feb 20251661632771364127
28 Mar 20251891833566354119
25 Apr 20251752635562332117
23 May 20252202625763360124
20 Jun 20252332527668309127
18 Jul 20252384124568341134
15 Aug 20252743918981609137
12 Sep 20253045718576610140
10 Oct 20253116918775544139
7 Nov 20253156017877612143
5 Dec 20253426922184808146
2 Jan 20263445523595737146
30 Jan 202636069233100995148
27 Feb 202636574261114728146
27 Mar 202637566260100822135
24 Apr 202635183294112876152
22 May 2026436663591271,432159
19 Jun 2026452763621181,668159
17 Jul 2026524863751321,877159
14 Aug 20266291053521241,747166
11 Sep 20266251533491261,567163
9 Oct 2026654137349135643166
6 Nov 20267881433531471,112164

The companies with the strongest one-year price moves are drawn. The S&P 500 line is dashed.

Biggest one-year moves

  1. 1Kiniksa Pharmaceuticals International, plcKNSA · $7.6B+150.5%1 year
  2. 2Amylyx Pharmaceuticals, Inc.AMLX · $3.7B+138.8%1 year
  3. 3Lantheus Holdings, Inc.LNTH · $6.6B+98.0%1 year
  4. 4Viatris Inc.VTRS · $22.1B+89.9%1 year
  5. 5Liquidia CorporationLQDA · $4.2B+81.6%1 year

Strongest against S&P 500

  1. 1Kiniksa Pharmaceuticals International, plcKNSA · $7.6B+59.0%vs S&P 500
  2. 2Amylyx Pharmaceuticals, Inc.AMLX · $3.7B+48.3%vs S&P 500
  3. 3Pacira BioSciences, Inc.PCRX · $1.5B+36.8%vs S&P 500
  4. 4Xeris Biopharma Holdings, Inc.XERS · $1.9B+31.8%vs S&P 500
  5. 5Bausch Health Companies Inc.BHC · $3.1B+30.9%vs S&P 500

Strongest against the sector itself

  1. 1Kiniksa Pharmaceuticals International, plcKNSA · $7.6B+43.2%vs sector
  2. 2Amylyx Pharmaceuticals, Inc.AMLX · $3.7B+33.9%vs sector
  3. 3Pacira BioSciences, Inc.PCRX · $1.5B+22.7%vs sector
  4. 4Xeris Biopharma Holdings, Inc.XERS · $1.9B+18.3%vs sector
  5. 5Bausch Health Companies Inc.BHC · $3.1B+17.1%vs sector

Which Drug Manufacturers - Specialty & Generic companies have the most revenue, and which grow fastest?

Teva Pharmaceutical Industries Limited has the highest Revenue among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $17,315 million. Viatris Inc. is next at $14,738 million. Liquidia Corporation has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Teva Pharmaceutical Industries Limited is the largest at $17,315 million, 17.5% ahead of Viatris Inc. Liquidia Corporation's growth is capped at 100% on the scoring scale; the full change over the last 12 months is 2273.7% from a $451 million base, with 19 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

Teva Pharmaceutical Industries Limited · $17,315 millionLeader
17.5% versus #2 · Viatris Inc.Gap
6/8 recent comparable periodsPersistence
24/28 companies · 490 observationsCoverage

What this means: Teva Pharmaceutical Industries Limited is the size to compare against; Liquidia Corporation is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Teva Pharmaceutical Industries Limited's growth falls below Liquidia Corporation's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue, by reported quarter

  • Teva Pharmaceutical Industries $4.1B
  • Viatris Inc. $3.8B
  • Bausch Health Companies Inc. $2.9B
  • Zoetis Inc. $2.5B
  • Elanco Animal Health Incorporated $1.4B
Revenue, by reported quarter
QuarterTeva Pharmaceutical IndustriesViatris Inc.Bausch Health Companies Inc.Zoetis Inc.Elanco Animal Health Incorporated
Dec 2021$4.1B$4.3B$2.2B$2.0B$1.1B
Mar 2022$3.7B$4.2B$1.9B$2.0B$1.2B
Jun 2022$3.8B$4.1B$2.0B$2.1B$1.2B
Sep 2022$3.6B$4.1B$2.0B$2.0B$1.0B
Dec 2022$3.9B$3.9B$2.2B$2.0B$985M
Mar 2023$3.7B$3.7B$1.9B$2.0B$1.3B
Jun 2023$3.9B$3.9B$2.2B$2.2B$1.1B
Sep 2023$3.9B$3.9B$2.2B$2.2B$1.1B
Dec 2023$4.5B$3.8B$2.4B$2.2B$1.0B
Mar 2024$3.8B$3.7B$2.2B$2.2B$1.2B
Jun 2024$4.2B$3.8B$2.4B$2.4B$1.2B
Sep 2024$4.3B$3.8B$2.5B$2.4B$1.0B
Dec 2024$4.2B$3.5B$2.6B$2.3B$1.0B
Mar 2025$3.9B$3.3B$2.3B$2.2B$1.2B
Jun 2025$4.2B$3.6B$2.5B$2.5B$1.2B
Sep 2025$4.5B$3.8B$2.7B$2.4B$1.1B
Dec 2025$4.7B$3.7B$2.8B$2.4B$1.1B
Mar 2026$4.0B$3.5B$2.5B$2.3B$1.4B
Jun 2026$4.1B$3.8B$2.9B$2.5B$1.4B
Sep 2026—————

Revenue growth, by reported quarter

  • Teva Pharmaceutical Industries −0.8%
  • Viatris Inc. 4.9%
  • Bausch Health Companies Inc. 13%
  • Zoetis Inc. −0.2%
  • Elanco Animal Health Incorporated 10%
Revenue growth, by reported quarter
QuarterTeva Pharmaceutical IndustriesViatris Inc.Bausch Health Companies Inc.Zoetis Inc.Elanco Animal Health Incorporated
Dec 2021—————
Mar 2022—————
Jun 2022−3.2%−10%−6.3%5.3%−8.1%
Sep 2022−7.5%−10%−3.1%0.6%−9.3%
Dec 2022−5.3%−11%−0.1%3.7%−11%
Mar 20230.0%−11%1.4%0.7%2.5%
Jun 20232.4%−4.8%10%6.2%−10%
Sep 20237.1%−3.3%9.4%7.4%4.1%
Dec 202315%−1.0%9.8%8.5%5.1%
Mar 20244.3%−1.8%11%9.5%−4.1%
Jun 20247.4%−3.1%11%8.3%12%
Sep 202413%−4.9%12%11%−3.6%
Dec 2024−5.1%−8.1%6.3%4.7%−1.5%
Mar 20251.9%−11%4.9%0.4%−1.0%
Jun 20250.3%−5.7%5.3%4.8%4.8%
Sep 20253.4%0.2%6.8%0.5%10%
Dec 202511%5.0%9.3%3.0%12%
Mar 20262.3%8.1%12%2.9%15%
Jun 2026−0.8%4.9%13%−0.2%10%
Sep 2026—————

24 of 28 companies report revenue, 24 of 28 revenue growth. On every company-comparison chart on this page the five leaders are drawn, level and change on separate charts, and a missing report breaks the line rather than being invented.

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue, every company
CompanyRevenueRevenue growthReported
Haleon plc HLN$5.6B2.2%Jun 2026
Teva Pharmaceutical Industries Limited TEVA$4.1B−0.8%Jun 2026
Viatris Inc. VTRS$3.8B4.9%Jun 2026
Bausch Health Companies Inc. BHC$2.9B13%Jun 2026
Zoetis Inc. ZTS$2.5B−0.2%Jun 2026
Elanco Animal Health Incorporated ELAN$1.4B10%Jun 2026
Perrigo Company plc PRGO$1.0B−3.1%Jun 2026
Neurocrine Biosciences, Inc. NBIX$959M39%Jun 2026
Amneal Pharmaceuticals, Inc. AMRX$796M9.8%Jun 2026
United Therapeutics Corporation UTHR$783M−2.0%Jun 2026
Hims & Hers Health, Inc. HIMS$753M38%Jun 2026
Alkermes plc ALKS$496M27%Jun 2026
Phibro Animal Health Corporation PAHC$397M4.8%Jun 2026
Lantheus Holdings, Inc. LNTH$388M2.7%Jun 2026
Indivior Pharmaceuticals, Inc. INDV$343M14%Jun 2026
HUTCHMED (China) Limited HCM$278M0.0%Jun 2026
Trulieve Cannabis Corp. TRLV$271M−10%Jun 2026
Prestige Consumer Healthcare Inc. PBH$266M6.4%Jun 2026
ANI Pharmaceuticals, Inc. ANIP$266M26%Jun 2026
Kiniksa Pharmaceuticals International, plc KNSA$244M55%Jun 2026
Supernus Pharmaceuticals, Inc. SUPN$219M33%Jun 2026
BioCryst Pharmaceuticals, Inc. BCRX$218M34%Jun 2026
Pacira BioSciences, Inc. PCRX$192M6.1%Jun 2026
Liquidia Corporation LQDA$172M1,811%Jun 2026
Alvotech ALVO$106M−39%Jun 2026
Xeris Biopharma Holdings, Inc. XERS$92M28%Jun 2026
Amylyx Pharmaceuticals, Inc. AMLX−$1M−101%Jun 2026

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

What to watch

Watch the next two reported quarters for growth persistence, margin conversion and whether the leader is gaining share without stretching working capital.

Which Drug Manufacturers - Specialty & Generic companies keep the most from each $100 of sales?

Liquidia Corporation has the highest OPM among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 49.8%. Indivior Pharmaceuticals, Inc. is next at 46.9%. The same company also has the highest Margin change, at +474.2 percentage points. 26 of 28 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Liquidia Corporation leads both opm at 49.8% and margin change at +474.2 percentage points.

Liquidia Corporation · 49.8%Leader
6.2% versus #2 · Indivior Pharmaceuticals, Inc.Gap
5/8 recent comparable periodsPersistence
26/28 companies · 482 observationsCoverage

What this means: Liquidia Corporation sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM, by reported quarter

  • Liquidia Corporation 50%
  • Indivior Pharmaceuticals, Inc. 47%
  • BioCryst Pharmaceuticals, Inc. 45%
  • United Therapeutics Corporation 42%
  • Zoetis Inc. 41%
OPM, by reported quarter
QuarterLiquidia CorporationIndivior Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.United Therapeutics CorporationZoetis Inc.
Dec 2021−353%5.4%−126%41%30%
Mar 2022−414%26%−100%62%40%
Jun 2022−229%28%−53%43%35%
Sep 2022−279%25%−23%61%36%
Dec 2022−121%16%−58%38%34%
Mar 2023−206%28%−41%56%36%
Jun 2023−477%25%−25%53%38%
Sep 2023−405%21%−14%54%37%
Dec 2023−583%16%−40%43%32%
Mar 2024−969%26%−16%53%37%
Jun 2024−743%14%8.0%45%38%
Sep 2024−656%30%6.6%55%39%
Dec 2024—18%−2.5%50%33%
Mar 2025—25%15%48%37%
Jun 2025−424%24%18%48%41%
Sep 20253.3%37%19%49%39%
Dec 202522%37%66%45%35%
Mar 202646%46%−2.5%42%37%
Jun 202650%47%45%42%41%
Sep 2026—————

Margin change, by reported quarter

  • Liquidia Corporation +474.2 pp
  • Indivior Pharmaceuticals, Inc. +23.4 pp
  • BioCryst Pharmaceuticals, Inc. +26.9 pp
  • United Therapeutics Corporation −6.2 pp
  • Zoetis Inc. 0.0 pp
Margin change, by reported quarter
QuarterLiquidia CorporationIndivior Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.United Therapeutics CorporationZoetis Inc.
Dec 2021—————
Mar 2022—————
Jun 2022−40.7 pp−8.2 pp+6.2 pp−6.6 pp−0.7 pp
Sep 2022−56.3 pp−5.5 pp+68.7 pp+9.2 pp−0.5 pp
Dec 2022+232.2 pp+10.7 pp+67.3 pp−3.2 pp+3.8 pp
Mar 2023+208.9 pp+2.1 pp+58.8 pp−6.3 pp−3.3 pp
Jun 2023−248.0 pp−3.1 pp+27.9 pp+9.3 pp+2.9 pp
Sep 2023−125.9 pp−4.0 pp+9.3 pp−7.2 pp+1.0 pp
Dec 2023−462.2 pp−0.4 pp+17.8 pp+4.9 pp−2.0 pp
Mar 2024−763.6 pp−1.3 pp+25.7 pp−3.5 pp+0.2 pp
Jun 2024−266.4 pp−11.0 pp+33.1 pp−7.8 pp+0.1 pp
Sep 2024−251.3 pp+9.0 pp+20.3 pp+0.8 pp+1.4 pp
Dec 2024−654.4 pp+2.0 pp+37.9 pp+7.4 pp+1.1 pp
Mar 2025−166.3 pp−1.2 pp+30.2 pp−4.4 pp+0.7 pp
Jun 2025+318.9 pp+9.5 pp+10.2 pp+3.7 pp+2.3 pp
Sep 2025+659.5 pp+6.9 pp+12.0 pp−5.8 pp+0.8 pp
Dec 2025+1,259.3 pp+19.5 pp+68.1 pp−4.7 pp+1.4 pp
Mar 2026+1,181.7 pp+20.9 pp−17.1 pp−6.5 pp−0.7 pp
Jun 2026+474.2 pp+23.4 pp+26.9 pp−6.2 pp0.0 pp
Sep 2026—————

26 of 28 companies report OPM, 27 of 28 margin change. The margin change chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Operating margin, every company
CompanyOPMMargin changeReported
Liquidia Corporation LQDA50%+474.2 ppJun 2026
Indivior Pharmaceuticals, Inc. INDV47%+23.4 ppJun 2026
BioCryst Pharmaceuticals, Inc. BCRX45%+26.9 ppJun 2026
United Therapeutics Corporation UTHR42%−6.2 ppJun 2026
Zoetis Inc. ZTS41%0.0 ppJun 2026
Bausch Health Companies Inc. BHC27%+9.1 ppJun 2026
Lantheus Holdings, Inc. LNTH26%+2.5 ppJun 2026
Haleon plc HLN24%+1.5 ppJun 2026
Neurocrine Biosciences, Inc. NBIX22%+1.0 ppJun 2026
Prestige Consumer Healthcare Inc. PBH21%−8.0 ppJun 2026
Amneal Pharmaceuticals, Inc. AMRX18%+2.8 ppJun 2026
Alkermes plc ALKS16%−8.3 ppJun 2026
ANI Pharmaceuticals, Inc. ANIP15%+7.8 ppJun 2026
Trulieve Cannabis Corp. TRLV13%−4.5 ppJun 2026
Viatris Inc. VTRS13%+3.1 ppJun 2026
Kiniksa Pharmaceuticals International, plc KNSA11%−1.7 ppJun 2026
Phibro Animal Health Corporation PAHC11%+0.3 ppJun 2026
Elanco Animal Health Incorporated ELAN8.6%+1.8 ppJun 2026
Pacira BioSciences, Inc. PCRX6.2%+1.2 ppJun 2026
Xeris Biopharma Holdings, Inc. XERS5.6%−0.7 ppJun 2026
Teva Pharmaceutical Industries Limited TEVA4.0%−17.4 ppJun 2026
Perrigo Company plc PRGO3.8%−1.5 ppJun 2026
HUTCHMED (China) Limited HCM0.3%+1.6 ppJun 2026
Supernus Pharmaceuticals, Inc. SUPN−2.5%−9.2 ppJun 2026
Alvotech ALVO−11%−21.5 ppJun 2026
Hims & Hers Health, Inc. HIMS−13%−17.7 ppJun 2026
Amylyx Pharmaceuticals, Inc. AMLX−138%−9,503.3 ppJun 2026

What to watch

Watch whether the next two comparable periods confirm the current margin change rather than reversing it.

Which Drug Manufacturers - Specialty & Generic companies earn the most profit?

Zoetis Inc. has the highest Net profit among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at $2,616 million. United Therapeutics Corporation is next at $1,311 million. Amneal Pharmaceuticals, Inc. has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Zoetis Inc. earns the most, $2,616 million of profit over the last 12 months, 99.5% above United Therapeutics Corporation. Amneal Pharmaceuticals, Inc. shows at least 100% on the scoring scale (5133.3% in full) growth from a profit base of $157 million. A fast rate from a small base matters less than a large profit that keeps coming.

Zoetis Inc. · $2,616 millionLeader
99.5% versus #2 · United Therapeutics CorporationGap
6/8 recent comparable periodsPersistence
25/28 companies · 509 observationsCoverage

What this means: Zoetis Inc. sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit, by reported quarter

  • Zoetis Inc. $691M
  • United Therapeutics Corporation $333M
  • Neurocrine Biosciences, Inc. $144M
  • Teva Pharmaceutical Industries −$576M
  • Indivior Pharmaceuticals, Inc. $122M
Net profit, by reported quarter
QuarterZoetis Inc.United Therapeutics CorporationNeurocrine Biosciences, Inc.Teva Pharmaceutical IndustriesIndivior Pharmaceuticals, Inc.
Dec 2021$414M$112M−$7M−$159M$36M
Mar 2022$595M$240M$14M−$955M$41M
Jun 2022$529M$116M−$17M−$232M$48M
Sep 2022$529M$239M$69M$56M$41M
Dec 2022$461M$132M$89M−$1.3B−$183M
Mar 2023$552M$241M−$77M−$220M$44M
Jun 2023$671M$259M$96M−$872M$39M
Sep 2023$596M$268M$83M$69M−$135M
Dec 2023$525M$217M$148M$463M−$77M
Mar 2024$599M$307M$43M−$139M$61M
Jun 2024$624M$278M$65M−$846M−$97M
Sep 2024$682M$309M$130M−$437M$22M
Dec 2024$581M$301M$103M−$217M$21M
Mar 2025$602M$322M$8M$214M$47M
Jun 2025$726M$310M$108M$282M$18M
Sep 2025$721M$339M$210M$433M$42M
Dec 2025$603M$364M$154M$480M$102M
Mar 2026$601M$275M$198M$369M$89M
Jun 2026$691M$333M$144M−$576M$122M
Sep 2026—————

Profit growth, by reported quarter

  • Zoetis Inc. −4.8%
  • United Therapeutics Corporation 7.4%
  • Neurocrine Biosciences, Inc. 33%
  • Teva Pharmaceutical Industries −304%
  • Indivior Pharmaceuticals, Inc. 578%
Profit growth, by reported quarter
QuarterZoetis Inc.United Therapeutics CorporationNeurocrine Biosciences, Inc.Teva Pharmaceutical IndustriesIndivior Pharmaceuticals, Inc.
Dec 2021—————
Mar 2022—————
Jun 20223.5%−33%−140%−210%−23%
Sep 2022−4.2%47%200%−81%52%
Dec 202211%18%——−608%
Mar 2023−7.2%0.4%−650%—7.3%
Jun 202327%123%——−19%
Sep 202313%12%20%23%−429%
Dec 202314%64%66%——
Mar 20248.5%27%——39%
Jun 2024−7.0%7.3%−32%—−349%
Sep 202414%15%57%−733%—
Dec 202411%39%−30%−147%—
Mar 20250.5%4.9%−81%—−23%
Jun 202516%12%66%——
Sep 20255.7%9.7%62%—91%
Dec 20253.8%21%50%—386%
Mar 2026−0.2%−15%2,375%72%89%
Jun 2026−4.8%7.4%33%−304%578%
Sep 2026—————

25 of 28 companies report net profit, 15 of 28 profit growth. The profit growth chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

Net profit, every company
CompanyNet profitProfit growthReported
Haleon plc HLN$762M−5.5%Jun 2026
Zoetis Inc. ZTS$691M−4.8%Jun 2026
United Therapeutics Corporation UTHR$333M7.4%Jun 2026
Bausch Health Companies Inc. BHC$258M74%Jun 2026
Neurocrine Biosciences, Inc. NBIX$144M33%Jun 2026
Indivior Pharmaceuticals, Inc. INDV$122M578%Jun 2026
BioCryst Pharmaceuticals, Inc. BCRX$78M1,460%Jun 2026
Lantheus Holdings, Inc. LNTH$75M−5.1%Jun 2026
Liquidia Corporation LQDA$75M—Jun 2026
Perrigo Company plc PRGO$75M−400%Jun 2026
Amneal Pharmaceuticals, Inc. AMRX$58M164%Jun 2026
Elanco Animal Health Incorporated ELAN$54M391%Jun 2026
Prestige Consumer Healthcare Inc. PBH$29M−38%Jun 2026
Kiniksa Pharmaceuticals International, plc KNSA$25M39%Jun 2026
ANI Pharmaceuticals, Inc. ANIP$23M229%Jun 2026
Phibro Animal Health Corporation PAHC$22M29%Jun 2026
HUTCHMED (China) Limited HCM$16M−96%Jun 2026
Pacira BioSciences, Inc. PCRX$5M−40%Jun 2026
Alkermes plc ALKS$1M−99%Jun 2026
Regencell Bioscience Holdings Limited RGC−$6M—Jun 2026
Xeris Biopharma Holdings, Inc. XERS−$31M—Jun 2026
Amylyx Pharmaceuticals, Inc. AMLX−$43M−860%Jun 2026
Supernus Pharmaceuticals, Inc. SUPN−$58M−364%Jun 2026
Alvotech ALVO−$67M−309%Jun 2026
Hims & Hers Health, Inc. HIMS−$86M−300%Jun 2026
Viatris Inc. VTRS−$119M−235%Jun 2026
Trulieve Cannabis Corp. TRLV−$406M−705%Jun 2026
Teva Pharmaceutical Industries Limited TEVA−$576M−304%Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current profit growth rather than reversing it.

Which Drug Manufacturers - Specialty & Generic companies earn the best return on capital?

Indivior Pharmaceuticals, Inc. has the highest ROCE among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 152.3%. BioCryst Pharmaceuticals, Inc. is next at 112%. Liquidia Corporation has the highest ROCE change at +127.9 percentage points, so level and change sit with different companies. 28 of 28 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Indivior Pharmaceuticals, Inc. leads ROCE at 152.3%, 40.3 percentage points above BioCryst Pharmaceuticals, Inc. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

Indivior Pharmaceuticals, Inc. · 152.3%Leader
36% versus #2 · BioCryst Pharmaceuticals, Inc.Gap
8/8 recent comparable periodsPersistence
28/28 companies · 526 observationsCoverage

What this means: Indivior Pharmaceuticals, Inc. sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

ROCE, by reported quarter

  • Indivior Pharmaceuticals, Inc. 152%
  • BioCryst Pharmaceuticals, Inc. 112%
  • Liquidia Corporation 51%
  • Zoetis Inc. 28%
  • United Therapeutics Corporation 21%
ROCE, by reported quarter
QuarterIndivior Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.Liquidia CorporationZoetis Inc.United Therapeutics Corporation
Dec 202118%−37%−39%23%14%
Mar 202219%−40%−46%26%18%
Jun 202220%−44%−32%27%17%
Sep 202220%−34%−35%26%18%
Dec 202228%−33%−32%25%17%
Mar 202332%−30%−28%24%16%
Jun 202331%−26%−46%25%17%
Sep 202338%−25%−54%25%18%
Dec 202352%−27%−74%25%19%
Mar 202442%−24%−53%25%22%
Jun 202442%−16%−64%26%22%
Sep 202451%−11%−51%26%22%
Dec 202467%−0.4%−64%31%22%
Mar 202569%10%−77%32%21%
Jun 202572%20%−77%32%21%
Sep 202568%30%−62%27%22%
Dec 2025135%109%−27%27%21%
Mar 2026112%120%18%28%24%
Jun 2026152%112%51%28%21%
Sep 2026—————

ROCE change, by reported quarter

  • Indivior Pharmaceuticals, Inc. +80.8 pp
  • BioCryst Pharmaceuticals, Inc. +92.2 pp
  • Liquidia Corporation +127.9 pp
  • Zoetis Inc. −4.0 pp
  • United Therapeutics Corporation +0.3 pp
ROCE change, by reported quarter
QuarterIndivior Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.Liquidia CorporationZoetis Inc.United Therapeutics Corporation
Dec 2021—————
Mar 2022—————
Jun 2022—————
Sep 2022—————
Dec 2022+10.2 pp+3.3 pp+6.9 pp+1.8 pp+3.2 pp
Mar 2023+13.3 pp+9.6 pp+18.4 pp−1.9 pp−1.5 pp
Jun 2023+11.4 pp+17.8 pp−14.7 pp−1.6 pp+0.3 pp
Sep 2023+18.3 pp+9.0 pp−18.8 pp−1.8 pp−0.1 pp
Dec 2023+23.2 pp+6.5 pp−41.3 pp−0.2 pp+1.3 pp
Mar 2024+9.5 pp+5.5 pp−25.6 pp+1.0 pp+5.9 pp
Jun 2024+11.0 pp+9.8 pp−17.2 pp+1.1 pp+4.1 pp
Sep 2024+12.5 pp+14.2 pp+2.7 pp+1.9 pp+3.8 pp
Dec 2024+15.3 pp+26.5 pp+9.2 pp+6.6 pp+3.3 pp
Mar 2025+26.9 pp+34.5 pp−23.5 pp+6.6 pp−1.3 pp
Jun 2025+29.4 pp+35.9 pp−13.6 pp+5.7 pp−0.6 pp
Sep 2025+17.3 pp+40.8 pp−11.0 pp+0.1 pp+0.9 pp
Dec 2025+68.0 pp+109.6 pp+37.6 pp−4.2 pp−1.2 pp
Mar 2026+42.9 pp+109.4 pp+94.7 pp−4.4 pp+2.9 pp
Jun 2026+80.8 pp+92.2 pp+127.9 pp−4.0 pp+0.3 pp
Sep 2026—————

28 of 28 companies report ROCE, 28 of 28 ROCE change. The ROCE change chart is drawn inside its usual range; a quarter far outside it (often a first quarter after listing or a near-zero base) is marked with an arrow at the edge, with its exact value in the hover card and the table.

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Return on capital, every company
CompanyROCEROCE changeReported
Indivior Pharmaceuticals, Inc. INDV152%+80.8 ppJun 2026
BioCryst Pharmaceuticals, Inc. BCRX112%+92.2 ppJun 2026
Liquidia Corporation LQDA51%+127.9 ppJun 2026
Zoetis Inc. ZTS28%−4.0 ppJun 2026
United Therapeutics Corporation UTHR21%+0.3 ppJun 2026
Neurocrine Biosciences, Inc. NBIX19%+4.4 ppJun 2026
Amneal Pharmaceuticals, Inc. AMRX17%+0.7 ppJun 2026
Xeris Biopharma Holdings, Inc. XERS17%+20.6 ppJun 2026
Phibro Animal Health Corporation PAHC16%+3.4 ppJun 2026
Lantheus Holdings, Inc. LNTH15%−9.2 ppJun 2026
Kiniksa Pharmaceuticals International, plc KNSA14%+13.0 ppJun 2026
Teva Pharmaceutical Industries Limited TEVA14%+1.2 ppJun 2026
Bausch Health Companies Inc. BHC14%+5.0 ppJun 2026
ANI Pharmaceuticals, Inc. ANIP11%+7.6 ppJun 2026
Haleon plc HLN10%+1.1 ppJun 2026
Prestige Consumer Healthcare Inc. PBH6.6%−3.9 ppJun 2026
Trulieve Cannabis Corp. TRLV6.6%+3.6 ppJun 2026
Alkermes plc ALKS6.0%−15.4 ppJun 2026
Viatris Inc. VTRS4.9%+0.9 ppJun 2026
Perrigo Company plc PRGO4.3%0.0 ppJun 2026
Alvotech ALVO4.2%−0.8 ppJun 2026
Elanco Animal Health Incorporated ELAN2.9%+1.2 ppJun 2026
Pacira BioSciences, Inc. PCRX2.4%−3.2 ppJun 2026
Supernus Pharmaceuticals, Inc. SUPN0.7%−4.0 ppJun 2026
HUTCHMED (China) Limited HCM−2.4%−1.0 ppJun 2026
Hims & Hers Health, Inc. HIMS−5.4%−13.4 ppJun 2026
Amylyx Pharmaceuticals, Inc. AMLX−67%+26.2 ppJun 2026
Regencell Bioscience Holdings Limited RGC−87%−13.4 ppJun 2026

What to watch

Watch whether the next two comparable periods confirm the current roce change rather than reversing it.

How are Drug Manufacturers - Specialty & Generic stocks valued against growth and quality?

Alkermes plc has the lowest PEG among the 28 Drug Manufacturers - Specialty & Generic companies compared here, at 0.57×. Neurocrine Biosciences, Inc. is next at 0.71×. Elanco Animal Health Incorporated has the lowest P/E at −61.8×, so level and change sit with different companies. 6 of 28 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Alkermes plc has the lowest comparable PEG at 0.57×, 19.7% below Neurocrine Biosciences, Inc. That would need today's multiple, the company's own history and steady growth to agree.

Alkermes plc · 0.57×Leader
19.7% versus #2 · Neurocrine Biosciences, Inc.Gap
0/8 recent comparable periodsPersistence
6/28 companies · 42 observationsCoverage

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison

PEG, by reported quarter

  • Alkermes plc 0.6
  • Neurocrine Biosciences, Inc. 0.7
  • Phibro Animal Health Corporation 1.4
  • United Therapeutics Corporation 1.9
  • Zoetis Inc. 2.1
PEG, by reported quarter
QuarterAlkermes plcNeurocrine Biosciences, Inc.Phibro Animal Health CorporationUnited Therapeutics CorporationZoetis Inc.
Dec 2021—————
Mar 2022—————
Jun 2022—————
Sep 2022—————
Dec 2022—————
Mar 2023—————
Jun 2023———0.44.7
Sep 2023———0.52.9
Dec 2023—0.9—0.33.0
Mar 2024———0.21.9
Jun 2024———0.64.5
Sep 2024———0.64.4
Dec 20242.21.11.40.63.8
Mar 2025———0.65.0
Jun 20250.6——0.62.1
Sep 2025—2.8—0.92.3
Dec 2025—0.7—1.22.3
Mar 2026———2.51.9
Jun 2026———1.92.1
Sep 2026—————

P/E, by reported quarter

  • Alkermes plc 132.1×
  • Neurocrine Biosciences, Inc. 24.0×
  • Phibro Animal Health Corporation 12.8×
  • United Therapeutics Corporation 17.5×
  • Zoetis Inc. 11.5×
P/E, by reported quarter
QuarterAlkermes plcNeurocrine Biosciences, Inc.Phibro Animal Health CorporationUnited Therapeutics CorporationZoetis Inc.
Dec 2021−78.1×—15.5×20.5×56.7×
Mar 2022—125.1×13.7×11.8×42.9×
Jun 2022——15.8×16.9×38.7×
Sep 2022—174.5×11.6×13.5×33.6×
Dec 2022—74.3×15.0×17.4×32.3×
Mar 2023——21.7×14.2×37.2×
Jun 202339.6×52.2×17.0×11.9×36.0×
Sep 202319.2×57.5×—11.8×35.1×
Dec 202313.0×51.8×31.7×10.5×38.7×
Mar 202410.4×37.1×39.8×10.3×32.4×
Jun 202414.1×40.8×281.1×13.2×33.8×
Sep 202413.8×30.2×52.4×14.4×36.4×
Dec 202412.7×40.5×44.0×13.2×29.6×
Mar 202515.4×36.1×27.2×11.4×29.6×
Jun 202513.5×35.7×21.5×10.4×26.8×
Sep 202514.6×32.5×24.2×14.9×24.7×
Dec 202519.1×29.6×16.4×15.7×20.9×
Mar 2026—19.8×23.5×20.2×18.8×
Jun 2026132.1×24.0×12.8×17.5×11.5×
Sep 2026—————

6 of 28 companies report PEG, 27 of 28 P/E.

PEG · lowest PEG

P/E · lowest P/E

All-company data · latest reported quarter

Valuation, every company
CompanyPEGP/EReported
Hims & Hers Health, Inc. HIMS3.857.6×Jun 2026
Lantheus Holdings, Inc. LNTH2.626.2×Jun 2026
Haleon plc HLN2.218.9×Jun 2026
Zoetis Inc. ZTS2.111.5×Jun 2026
United Therapeutics Corporation UTHR1.917.5×Jun 2026
Phibro Animal Health Corporation PAHC1.412.8×Jun 2026
Neurocrine Biosciences, Inc. NBIX0.724.0×Jun 2026
Alkermes plc ALKS0.6132.1×Jun 2026
Teva Pharmaceutical Industries Limited TEVA—21.1×Jun 2026
Viatris Inc. VTRS—−52.5×Jun 2026
Elanco Animal Health Incorporated ELAN—−61.8×Jun 2026
Kiniksa Pharmaceuticals International, plc KNSA—61.0×Jun 2026
Amneal Pharmaceuticals, Inc. AMRX—35.1×Jun 2026
Liquidia Corporation LQDA—51.2×Jun 2026
Amylyx Pharmaceuticals, Inc. AMLX—20.2×Jun 2026
Indivior Pharmaceuticals, Inc. INDV—14.1×Jun 2026
Supernus Pharmaceuticals, Inc. SUPN—27.4×Jun 2026
Bausch Health Companies Inc. BHC—−1.7×Jun 2026
Prestige Consumer Healthcare Inc. PBH—13.0×Jun 2026
HUTCHMED (China) Limited HCM—103.3×Jun 2026
Trulieve Cannabis Corp. TRLV—−13.3×Jun 2026
Perrigo Company plc PRGO—−0.8×Jun 2026
BioCryst Pharmaceuticals, Inc. BCRX—−6.6×Jun 2026
Xeris Biopharma Holdings, Inc. XERS—83.3×Jun 2026
Alvotech ALVO—−13.3×Jun 2026
ANI Pharmaceuticals, Inc. ANIP—17.6×Jun 2026
Pacira BioSciences, Inc. PCRX—68.2×Jun 2026

What to watch

Watch whether the next two comparable periods confirm the current p/e rather than reversing it.

What can make this comparison misleading?

This Drug Manufacturers - Specialty & Generic comparison names 4 specific ways its own evidence can mislead, all listed below. All 28 companies here report on comparable dates, so no rank carries a stale marker. A high growth rate can still come from a very small starting figure.

Keep these limits visible

  • A high growth rate can come from a very small starting figure. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary, or look high because the capital base is small. It is best read beside margin, cash flow and how much is spent back on the business.
  • The 4-Factor Sector Score ranks published data only. Management quality, upcoming events and risks are not part of it.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.

How was this comparison built?

This comparison is built from the reported filings of 28 Drug Manufacturers - Specialty & Generic companies, normalized to a common $ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Sep 2026 and market data through 4 November 2026.

FundamentalsThrough Sep 2026 · up to 20 quarters per company
Market dataThrough 4 November 2026 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and old evidence lowers confidence and pulls the 0 to 100 score toward the middle.

What else do people ask about Drug Manufacturers - Specialty & Generic stocks?

These 22 answers restate the Drug Manufacturers - Specialty & Generic comparison above in question form. Every one is computed from the same 28 companies and the same reported filings as the rankings and charts, current through Sep 2026. Price and relative-strength answers run through 4 November 2026. Nothing here is estimated, and none of it is a recommendation.

Is the Drug Manufacturers - Specialty & Generic sector outperforming S&P 500?

Drug Manufacturers - Specialty & Generic has done better than the S&P 500 by 22.3% over 52 weeks and by 11.9% over 13 weeks.

15 of 28 companies we track are beating the S&P 500 on relative strength (how a share price has done against the index over recent months), and 11 of 28 are ahead of the industry itself.

Which Drug Manufacturers - Specialty & Generic company is largest by revenue?

Teva Pharmaceutical Industries Limited leads with revenue of $17,315 million, based on 24 of 28 comparable companies through Jun 2026.

Which Drug Manufacturers - Specialty & Generic company is growing fastest?

Liquidia Corporation has the fastest current revenue growth at 100%, across 24 of 28 comparable companies.

Which Drug Manufacturers - Specialty & Generic company has the strongest 4-Factor Sector Score?

Neurocrine Biosciences, Inc. ranks first at 66.3 out of 100, with 81.1% of the evidence available. The score ranks published data; it is not a recommendation.

Which Drug Manufacturers - Specialty & Generic company has the lowest comparable PEG?

Alkermes plc has the lowest comparable PEG at 0.57, among 6 of 28 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Drug Manufacturers - Specialty & Generic comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Sep 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four parts add up directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or old evidence moves only that part toward the middle.

Which Drug Manufacturers - Specialty & Generic company is the biggest?

Teva Pharmaceutical Industries Limited is the largest, with revenue of $17,315 million over the last 12 months, ahead of Viatris Inc. at $14,738 million. That covers 24 of 28 companies with comparable reporting through Jun 2026.

Which Drug Manufacturers - Specialty & Generic company has the best profit margins?

Liquidia Corporation has the highest operating margin at 49.8%, from 26 of 28 comparable companies. Liquidia Corporation shows the biggest improvement (+474.2 percentage points; the chart above shows the starting level). A high margin matters most when it is steady or rising, not when it is at a peak.

Which Drug Manufacturers - Specialty & Generic company makes the most profit?

Zoetis Inc. earns the most, at $2,616 million of net profit over the last 12 months, from 25 of 28 comparable companies.

Amneal Pharmaceuticals, Inc. has the fastest profit growth at the 100% cap of the scoring scale, though growth off a small or recovering profit base overstates how much has actually changed.

Which Drug Manufacturers - Specialty & Generic company earns the highest return on capital?

Indivior Pharmaceuticals, Inc. leads on return on capital employed at 152.3%, across 28 of 28 companies. A high return that repeats for years shows a lasting business, while a single high reading can come from a small capital base or one good year.

Which Drug Manufacturers - Specialty & Generic stock has the lowest PEG ratio?

On PEG (where a lower number means a lower price for what the company earns), Alkermes plc has the lowest at 0.57×. Only 6 of 28 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a ranking of the whole industry.

A low multiple is a reason to look closer at the business, not a conclusion on its own.

Is the Drug Manufacturers - Specialty & Generic sector beating the market?

Drug Manufacturers - Specialty & Generic has done better than the S&P 500 by 22.3% over the last 52 weeks and by 11.9% over 13 weeks, measured on an equal-weight index of its current members.

Inside the sector, 15 of the 28 companies we track are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Drug Manufacturers - Specialty & Generic stock has the strongest price momentum?

Kiniksa Pharmaceuticals International, plc has the strongest relative strength against the S&P 500, meaning its share price has done best against the index. A price can move well before the business results back it up, and sometimes without them.

Which Drug Manufacturers - Specialty & Generic company has the highest 4-Factor score?

Neurocrine Biosciences, Inc. scores 66.3 out of 100, with 81.1% of the evidence available, from 26.1 points on growth and earnings, 18.2 on capital efficiency, 13.8 on valuation and 8.2 on relative strength. It ranks published data only; management quality, upcoming events and risks are not part of the score.

How many Drug Manufacturers - Specialty & Generic companies does this comparison cover, and over what period?

This comparison covers 28 listed companies over up to 20 reported quarters of fundamentals, ending Sep 2026, plus weekly price and relative-strength history. Membership is the full sector list, nothing is dropped for having thin data.

What is the total market cap of the Drug Manufacturers - Specialty & Generic sector?

The 28 Drug Manufacturers - Specialty & Generic companies on this page carry $280,190 million of combined market value. Teva Pharmaceutical Industries Limited is the largest at $48,733 million, about 17% of the sector's total on its own.

Market value moves with price, so this reading is dated 4 November 2026.

What is the Drug Manufacturers - Specialty & Generic sector's P/E ratio?

The median price-to-earnings ratio across the 28 Drug Manufacturers - Specialty & Generic companies on this page is 26.2×, measured on the 20 that report a comparable figure.

A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 4 November 2026.

How is the Drug Manufacturers - Specialty & Generic sector performing?

15 of the 28 Drug Manufacturers - Specialty & Generic companies we track are doing better than the S&P 500 on relative strength (how a share price has done against the index over recent months).

The sector itself is 22.3% ahead of S&P 500 over 52 weeks on an equal-weight index of its current members.

How many Drug Manufacturers - Specialty & Generic stocks are listed in the US?

This comparison covers 28 listed Drug Manufacturers - Specialty & Generic companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Sep 2026. Membership is the full industry list, nothing is dropped for having thin data.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing figures are never estimated, copied forward or swapped for a similar-looking line, and a company with missing evidence has its score pulled toward the middle rather than scored as bad.

Is this advice?

No, every figure here is worked out by code from company filings and market data, for research. It does not account for your situation and is not a substitute for advice from a registered adviser.

More lists

Every Sector Alpha list, grouped

Stock screens

Multibagger study listUndervalued stocksMomentum stocksBreakout stocksHigh growth stocks

Market lists

Stock market this weekNifty 50 companiesNifty Next 50 companies52 week high & low52 week low stocksDividend stocksBonus shares & stock splitsSmall & mid cap stocksPenny stocksInvITs in IndiaREITs in India

Themes

Defence stocksGold & silver stocksCopper & metal stocksSemiconductor stocksAI & data centre stocks

Sectors

Top 25 sectorsIT stocksBank stocksPharma stocksPower & green energy stocksOil & gas stocksReal estate, REIT & cementHotel stocksGold loan companies

US stocks

All US stock listsUS stock market this weekNasdaq 100 companiesS&P 500 companiesDow Jones 30 stocksTop US companiesUS tech stocksUS stock screenerUndervalued US stocksUS penny stocks

Crypto

Cryptocurrencies by market capCrypto market todayCrypto market this weekCrypto prices in INRCrypto gainers & losersMeme coinsAI crypto coinsAltcoinsNew crypto coinsStablecoinsCoins beating Bitcoin

Every US industry against its index · What changed this week · Plain-text data
Sector Alpha, written by code from the published numbers · Fundamentals through Sep 2026 · Prices through 4 November 2026. Every ranking is worked out by code from reported figures. Missing values stay missing.

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.